Department of Immunobiochemistry

Centrum für Biomedizin und Medizintechnik Mannheim (CBTM)

European Center for Angioscience (ECAS)

Medical Faculty Mannheim, Heidelberg University

Adelheid.cerwenka(at)medma.uni-heidelberg.de

Adelheid Cerwenka is head of the Department of Immunobiochemistry at the CBTM and ECAS. She pursued her graduate training at the Institute of Immunology at the University of Vienna. She then moved to the laboratory of Richard Dutton at the University of California and the Trudeau Institute in New York. In the laboratory of Lewis Lanier at the University of California in San Francisco she performed further postdoctoral training. She moved on setting up her own group at the German Cancer Research Center in Heidelberg. Since 2017 she is full professor at the Medical Faculty in Mannheim.

Qualifications and Scientific Curriculum

Diploma in Pharmacy, Institute of Immunology, University of Vienna, Austria

PhD, Institute of Immunology, University of Vienna, Austria

Postdoctoral Fellow, University of California, San Diego, CA, USA and at the Trudeau Institute, New York, USA

Postdoctoral Fellow, DNAX Research Institute and University of California, San Francisco, USA

Head of Laboratory, Division of Autoimmune Diseases, Novartis Research Institute, Vienna, Austria

 

Junior Group Leader “Innate Immunity”, German Cancer Research Center, Heidelberg, Germany

 

Full Professor, Medical Faculty Mannheim, Heidelberg University, Germany

1986-1991

1991-1995

1996-1998

1998-2001

2001-2003

2003-2016

since 2017

Selected publications​

  1. Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski L, Lorenz H, Brors B, Cerwenka A: Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc Natl Acad Sci U S A, pii:201720564, 2018.

  2. Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A: Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis, J Hepatol, 68:421-30, 2018.

  3. De Ponti A, Wiechert L, Stojanovic A, Longerich T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P: Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9. Int J Cancer, 136:2458-63, 2015.

  4. Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, Textor S, Cerwenka A: Metalloprotease-mediated shedding of B7-H6, the ligand of the activating receptor NKp30, from tumor cells, Cancer Res, 74:3429-40, 2014.

  5. Rölle A, Pollmann J, Ewen E, Halenius A, Hengel H, Cerwenka A. IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion in HCMV infection. J Clin Invest, 124:5305-16, 2014.

  6. Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A: CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-g production in response to mature dendritic cells. J Immunol, 192: 4184-91, 2014.

  7. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A: Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood, 122:684-93, 2013.

  8. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A:  Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors” J Exp Med, 209:2351-65, 2012.

  9. Cerwenka A, Baron JL, Lanier LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A, 98:11521-6, 2001.

  10. Cerwenka A, Bakker BH,  McClanahan T, Wagner J, Wu J, Phillips JH, and Lanier LL: Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity, 12: 721-7,       2000.

CRC1366

European Center for Angioscience

Medical Faculty Mannheim
Heidelberg University
Ludolf-Krehl-Straße 13-17
D-68167 Mannheim

Phone +49 621/383-71450